Alchemab Therapeutics today announced that it has initiated a Phase 1 first-in-human study of its antibody therapy ATLX-1282, licensed to Eli Lilly and Company in May 2025. According to the company, Lilly will lead later development and commercialization of ATLX-1282, while Alchemab conducts the ini…
Anavex Life Sciences has announced findings from its Phase IIb/III Alzheimer’s trial in which 30 mg daily oral blarcamesine led to cognitive outcomes in a “Precision Medicine” population (called ABCLEAR3) that the company says approximate normal aging rather than typical Alzheimer’s decline. The res…
A new retrospective cohort study demonstrates that hyperbaric oxygen therapy (HBOT) can significantly improve cognitive outcomes in adults who suffered a traumatic brain injury (TBI) during childhood and continue to experience post-concussion syndrome (PCS). The research was conducted by the Sagol Center for Hyperbaric Medicine and Research at Shamir Medical Center and Tel Aviv University, […] The post Study finds HBOT improves long-term post-concussion cognitive function appeared first on Longevity.Technology.
How a ‘special economic zone’ is enabling one company to offer longevity-focused gene therapies to clients, including Khloé Kardashian. The recent revelation that Khloé Kardashian has received a gene therapy purported to promote tissue rejuvenation came as something of a surprise to many. The celebrity influencer received the capillary-boosting VEGF treatment from regenerative medicine specialist […] The post Keeping up with the longevity gene therapies appeared first on Longevity.Technology.
Maze Therapeutics has announced positive results from the Phase 1 trial of MZE782, an oral SLC6A19 inhibitor designed to treat phenylketonuria (PKU) and chronic kidney disease (CKD). The randomized, double-blind, placebo-controlled study involved 112 healthy adult volunteers and evaluated single and…
Eleanor Davies, Global DeSci Lead at Sei Development Foundation, on how DeSci can reshape funding for aging science and healthspan. Science in 2025 is deeply under threat. While a fortunate few labs at prestigious institutions continue to pull in grants, the collapse of funding from the United State…
XPRIZE Healthspan EVP Jamie Justice explains why early career researchers should jump into the world’s biggest healthspan competition. How do we measure healthy aging? Despite billions of dollars flowing into longevity research, there is no universally accepted way to determine if a new therap…
New partnership aims to put epigenetic testing directly into the hands of consumers, with providers likely next in line. TruDiagnostic, already well known for its methylation and epigenetic biomarker testing, has partnered with Infinite Epigenetics to expand access beyond clinics and research settin…
Big Pharma leaders embrace GLP-1s as longevity drugs as debate grows on what this means for patients, pipelines and policy. At the twelfth Aging Research and Drug Discovery meeting (ARDD) in Copenhagen, the air was heavy with expectation; the conference has long been a forum where academia, biotech and pharma test their ideas, but this […] The post GLP-1s claim the longevity stage at ARDD appeared first on Longevity.Technology.
BioAge Labs, in partnership with HitGen, has initiated a Phase 1 clinical trial of BGE-102, a novel, orally available small-molecule inhibitor of NLRP3 that penetrates the brain, according to the company. The study will evaluate single and multiple ascending doses (SAD/MAD), with initial SAD data ex…
Genflow Biosciences has entered into two Confidential Disclosure Agreements (CDAs) with leading animal health companies, the company said. These agreements are intended to facilitate data exchange and initiate discussions on potential collaborations. The CDAs align with Genflow’s strategy to apply i…
Annovis Bio, Inc. has published results in Biomolecules showing that its newly developed dihydrate crystal form of buntanetap, which contains two moles of water, retains essentially the same pharmacokinetic (absorption, clearance, metabolism) profile as its original anhydrous form in studies involvi…
Company advances candidate targeting senescent cells into US study with potential applications beyond dermatology. Rubedo Life Sciences has announced that the US Food and Drug Administration has cleared its Investigational New Drug application for RLS-1496, a selective modulator of glutathione perox…
Cyclo Therapeutics, through a collaboration with Rafael Holdings, reported preliminary findings from a Phase 3 sub-study of its investigational therapy Trappsol® Cyclo™ (hydroxypropyl-beta-cyclodextrin) for Niemann-Pick Disease Type C1 (NPC1). The open-label, single-arm trial assessed patients young…
Rubedo Life Sciences has announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for RLS-1496 to begin a Phase 1b/2a clinical trial in patients with actinic keratosis, according to the company. RLS-1496 is a first-in-class, selective glut…
David Sinclair’s Harvard lab uses K-Dense Beta to develop an ‘uncertainty-aware’ biological aging clock in a matter of weeks. Generative AI startup Biostate AI has entered the race to accelerate biomedical discovery with the launch of K-Dense Beta, a multi-agent AI system designed to compress research timelines from years to days. The company’s technology has […] The post New AI tool demonstrates potential to accelerate longevity research appeared first on Longevity.Technology.
Geneva College of Longevity Science President Dominik Thor on education, evidence and the adoption of longevity technologies. The Global Longevity Summit, entitled Mastering the Aging Clock: The Science of Longevity, will convene in Geneva this October, bringing together international leaders in science, medicine and innovation under the banner Transform Your Practice and Patient Care. With […] The post ‘It’s time to bring innovations from bench to bedside’ appeared first on Longevity.Technology.
A new study conducted by Aviv Clinics in collaboration with the Sagol Center at Shamir Medical Center and Weizmann Institute examines hyperbaric oxygen therapy (HBOT) as a biologically based treatment for long-term post-traumatic stress disorder (PTSD). The research focused on 56 male veterans with …
Humacyte, Inc. announced the publication of preclinical results assessing its coronary tissue engineered vessel (CTEV) as a graft in coronary artery bypass surgery (CABG) in a non-human primate model. According to the company, the CTEV remained open (patent) for six months, recellularized with host …
Character Biosciences, a precision medicine company focused on polygenic diseases, has appointed four senior executives to its leadership team. Those additions are Robert Kim, M.D., MBA as Chief Medical Officer; Daniel Elgort, Ph.D. as Chief Data & Analytics Officer; Josh Buddle as Head of Clini…
